Abstract
Micro-RNAs are a novel class of single-strand non-coding RNAs, which play an important role in tumorigenesis. This investigation aimed to evaluate associations between the hsa-miR-27a (rs895819 T > C) and hsa-miR-125a (rs12976445 C > T) gene variations and the risk of PCa. In the present case–control investigation, we have obtained 300 peripheral blood samples, consisting of 150 subjects with PCa and 150 healthy men. The genotype frequencies of hsa-miR-27a and hsa-miR-125a gene variations evaluated using the PCR–RFLP technique. Based on our findings, the genotype frequencies did not reveal a significant association between the rs895819T and rs12976445C variations and the risk of PCa in the three heredity models (P > 0.05). Minor alleles C and T of rs895819 and rs12976445 did not show an increased risk of PCa progression (P > 0.05). Our findings indicated that the hsa-miR-27a and hsa-miR-125a gene variations are not increased PCa predisposition in the Iranian population.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Prostate cancer (PCa) is one of the most common medical problems in men with a high mortality rate worldwide [29]. The molecular investigation indicates that advanced and metastatic cases are the monoclonal PCa and caused by a single colony resulting from the proliferation and development of the tumor [4]. Epidemiological surveys have recommended that multiple genes involved in prostate carcinogenesis [24]. Previous investigations endeavor to the recognition of pathways and genes that plays crucial biology likely roles in the etiology of a PCa. From this reason, many surveys evaluated the associations of specific single nucleotide polymorphism (SNP) or haplotypes groups in reliable candidate susceptibility genes [20, 24] including the androgen receptor, telomere-related genes (TERT and TET), and microRNAs [1, 6, 12]. Has-miR-27a is assumed as an oncogene, found in the 19p13.13 chromosome, involving an exon, which plays an important role in malignancies such as colorectal cancer (CRC) [3]. The presence of rs895819 variation within the has-miR-27a gene is located on chromosome 19p13.12, which could change the secondary structure, aberrant expression, and dysfunction of the target gene [28]. Has-miR-27a (rs895819) is a stem-loop structure variant, which affects in the mature has-miR-27a function. The has-miR-27a rs895819 variation is an unusual miRNA-SNP, which due to the location in the coding region of the pre- has-miR-27a hairpin in the stem-loop digested by Dicer enzyme in the pre-miRNA maturation procedures [26]. It has shown that the has-miR-27a controlled by the Androgen hormone and can create positive feedback with the first loop [8]. Previous investigations have shown that rs895819 variation acts a critical role in cancerogenesis of several cancers such as pancreas, liver, lung, and PCa [30]. The has-miR-125a gene located on chromosome 19q13.41, which consisting of MIR99B and MIR7E genes. Previously, reported that the has-miR-125a decreased expression levels in several cancers and disorders including, systemic lupus erythematosus (SLE), breast, gastric, ovarian and verrucous carcinomas [23]. Molecular investigation revealed that the hsa-miR-125a rs12976445 variant could lead to a decrease in the level of hsa-miR-125a gene expression. The presence rs12976445 variation may interrupt a possible GATA-1 site and generated a truncate hsa-miR-125a transcription [15]. Several surveys have shown that the relationship between rs12976445 variation and the risk of several disorders such as recurrent pregnancy loss (RPL), breast cancer (BC), autoimmune thyroid disease, chronic periodontitis, and PCa [7, 10, 15, 27]. This study aimed to assess the relationship between has-miR-27a (rs895819) and has-miR-125a (rs12976445) gene variations and the risk of PCa in Iranian people.
Materials and methods
Patients’ selection
We designed a case–control investigation to assess 300 peripheral blood samples, which involving 150 PCa patients and 150 healthy men, ages matched and no history of other malignancies. All subjects were referred to the department of pathology Imam Khomeini Hospital of Tehran, from May 2014 to April 2015. Our survey was approved the Ahar Branch Islamic Azad University of Iran and written informed consent collected from all of the individuals. Before the sample collection, all PCa patients were assessed according to the standard clinical protocol, including digital rectal exam (DRE), abdominal and pelvic ultrasonography, and appraisal prostate-specific antigen (PSA) level of serum. In addition, the biopsies obtained from the PCa patients were confirmed histopathologically. In the control group, we included the healthy men ages matched, who had been normal PSA levels, without historical malignancies and the same geographical region. The individuals with an abnormal PSA level, unusual DRE, self-reported a disorder and family history of PCa were excluded from this study.
Genotyping
To isolation of genomic DNA from white blood cells, we have collected 2 ml peripheral blood from all subjects in the tubes containing anticoagulant EDTA, using the salting-out method [18]. For has-miR-27a (rs895819) and has-miR-125a (rs12976445) gene amplification were used the primer sequence (Table 1) as described previously [22]. The PCR condition for has-miR-27a (rs895819) and has-miR-125a (rs12976445) was as follow: the initial denaturation was 94 °C for 5 min, then, repeated 35 cycles in the denaturation 94 °C for 30 s, the annealing temperatures 64 °C and 60.8 °C for 30 s, and 72 °C in 30 s as the extension temperature, respectively.
We were used the PCR–RFLP method for determine genotype frequencies for has-miR-27a (rs895819) and has-miR-125a (rs12976445). The PCR product for the rs895819 and rs12976445 variations was digested (12 h at 37 °C) using Hpy1881 and BaeG enzymes (Thermo Fisher Scientific company), respectively (Table 1). To separated PCR product digestion used the 4% agarose gel electrophoresis.
Statistical analysis
To the analysis of the genotype and allele distribution of has-miR-27a (rs895819) and has-miR-125a (rs12976445) variations between groups, were used the multivariate logistic regression and chi-square tests. Statistical assessment was performed using SPSS 25.0 software (SPSS Inc. Chicago, IL) and a P value < 0.05 was considered as statistically significant.
Results
The mean age characteristics of the PCa patients studied were 48.81 ± 12.37 (range 34–56) years and 45.23 ± 5.39 (range 30–52) years for healthy men. In our investigation, we have involved the age-matched subjects and the same ethnicity. The genotype frequencies of the has-miR-27a (rs895819) variant were obtained (TT = 33, TC = 71, and CC = 46) and (TT = 34, TC = 72, and CC = 44) in patients and healthy men, respectively (P = 0.967). These findings did not show a significant difference between case and control groups (Table 2).
The genotype frequencies of has-miR-125a (rs12976445) polymorphism has shown (CC = 41, CT = 81, and TT = 21) and (CC = 40, CT = 77, and TT = 33) in case and control groups, respectively (P = 0.770). However, our results revealed no significant association between the rs12976445 variant and the risk of PCa (Table 3). We have evaluated the genotype frequencies in the co-dominant, dominant and recessive heredity patterns in two groups. Importantly, there was no positive association between has-miR-27a (rs895819) and has-miR-125a (rs12976445) gene polymorphisms in three genetic models with the risk of PCa (P > 0.05) (Tables 2 and 3).
In addition, we have also assessed the relationship between the allele frequencies of rs895819 and rs12976445 variants and the risk of PCa between groups. Minor alleles C and T of rs895819 and rs12976445 did not show an increased risk of PCa progression (P > 0.05). (P = 0.806; OR 1.041; 95% CI 0.755–1.435) and (P = 0.623; OR 0.923; 95% CI 0.670–1.272), respectively (Tables 2 and 3).
We have also assessed the relationship between the genotype frequencies for has-miR-27a (rs895819) and has-miR-125a (rs12976445) polymorphisms in the PCa patients with clinicopathological and demographic characteristics including age at diagnosis, tumor stage, Gleason score, the rate of cell growth and PSA serum levels. The findings disclosed that the has-miR-27a (rs895819) variant was significantly associated with the PSA (P = 0.001) level. Interestingly, the genotype frequencies of the has-miR-125a (rs12976445) variant revealed a significant association with the Gleason score (P = 0.001) of the clinical characteristics of the PCa patients (Table 4).
Discussion
The male reproductive system containing the prostate gland, which several environmental factors, such as family history, obesity, the use of some drugs and sexually transmitted diseases, acts a crucial function in cancerogenesis and PCa progression [16]. In addition, a large number of genetic variations and epigenetic changes have recognized as having important roles in the inflammatory prostate and development of PCa [9, 14]. To date, miRNAs have proposed that as diagnostic or prognostic biomarkers in cancer investigations. However, the miRNAs molecules are involved in the cancerogenesis of PCa, as well as the identification of suitable therapeutic targets that are important regulatory molecules for cancer detection pathways [21]. Our investigation is an initial case–control survey on the men Iranian. Since there were no details on the relationship between rs895819 and rs12976445 variations and the risk of PCa, we have also trying to prepare findings related to the developing of PCa. We have analyzed the association between the has-miR-27a (rs895819) and has-miR-125a (rs12976445) gene polymorphisms with the risk of PCa progression. Several surveys have assessed the potential impact of SNPs miRNA genes with the risk of PCa, which revealed conflicting results. Until now, a single survey by Nikolić et al. has attempted to evaluate the relationship between three miRNA gene polymorphisms including hsa-miR-499, hsa-miR-196a2 and hsa-miR-27a (rs895819) with the PCa progression in the Serbian population. They have assessed 355 PCa patients, 353 benign prostatic hyperplasia and 312 healthy individuals as a control group. The findings revealed that the minor allele C of rs895819 was significantly increased the risk of PCa progression. These findings revealed that early manifestation of the positive association between the rs895819 variant and the risk of developing and metastasis of PCa patients [22]. Our findings conflicted with the results referring to the potential roles of genetic variations in the has-miR-27a (rs895819) gene with the risk of PCa reported previously. Chen et al. investigated the association between rs11614913 with the risk of cancers. The rs895819 variant was correlated with a reduced tumor risk in Caucasians and BC, whereas a significantly advanced risk of progressing malignancy could be identified in CRC [2]. According to the previous investigation, has-miR-27a is implicated in metastasis of many types of malignancy, acting as an oncogene and regulate the target gene expression such as Forkhead box protein O1 (FOXO1), B-cell translocation gene 2 (BTG2), and human prohibitin gene (PHB) [13, 19, 31]. Surveys have declared that the presence of SNPs in miRNA could be changed miRNA expression levels and miRNA maturation processing. Furthermore, due to the T to C nucleotide change in pre-has-miR-27a can lead to decreased has-miR-27a gene expression levels and increased the susceptibility of the individual to malignancy [22]. However, differences in ethnicity and genetic backgrounds between various populations could have a significant effect on carcinoma susceptibility.
To date, there are little data regarding the possible association between the rs12976445 variant and the risk of PCa. Hence, we have assessed the relationship between the has-miR-125a (rs12976445) variant with the risk of PCa. Our results indicated an inverse association between the rs12976445 polymorphism with the risk of PCa in Iranian. There are discrepancies in the reported association between the rs12976445 and the risk of PCa.
Firstly, Feng et al. evaluated the association between rs1434536 C > T nucleotide change in a has-miR-125b binding location in the 3´-UTR of bone morphogenetic protein membrane receptor type IB gene (BMPR1B) and PCa susceptibility.
They have assessed 247 PCa patients and 278 healthy men using dual-luciferase reporter assay to evaluate the binding ability of has-miR-125b to target transcript. The findings revealed that CT/TT genotype increased the risk of PCa and contributed as a genetic predisposition factor for PCa progression [7].
Recently, Damodaran et al. evaluated several SNPs in has-miR146a (rs73318382, rs57095329 and rs2910164), has-miR-196a2 (rs11614913) and has-miR-125a (rs41275794, rs12976445, rs10404453 and rs1297533) in 100 cases with PCa and 100 healthy men. They were shown that the CC genotype of has-miR-125a (rs12976445) variant increased risk for PCa progression [5].
The discrepancy to the findings reported formerly [5] may be regarding the differences in genetic backgrounds, sample size, geographical location, different ethnicity, and race and criteria sample selection.
According to previous evidence, the nucleotide change in the has-miR-125a (rs12976445) gene related to several malignancies.
Jiao et al. were an assessed correlation between the has-miR-125a (rs12976445) with the survival of BC patients. The findings showed that this nucleotide change was significantly associated with survival in three genetically models including co-dominant, recessive, and dominant. However, this finding proposed that the rs12976445 variant applied as a prognostic value for BC patients [11]. In addition, Feng et al. evaluated the relationship between the rs12976445 polymorphism with the risk of intervertebral disc degeneration (IDD) and the findings showed that this polymorphism was significantly increased the risks of IDD [17].
To the best of our education, this is the early investigation in Iranian people exploring the association of has-miR-125a and has-miR27a polymorphisms with PCa susceptibility. The has-miR-125 gene family comprising several members including, has-miR-125a, has-miR-125b-1, and has-miR-125b-2, which were located in a different cytogenetic situation [25]. According to previous investigations has been declared that the has-miR-125a gene expression decreased in BC tissues and play as tumor suppressors [17, 23, 25] by affecting to the ETS1 gene through ERBB2 and ERBB3 pathway [17]. Although this is the particular survey which was assessed the association of rs12976445 and rs895819 variations with PCa, we did not reveal significant effects to PCa susceptibility.
The findings contradiction can be impressed by several factors such as diversity between the subjects groups assessed, geographic regions, race, ethnicity, and genetics background or error analysis. In the other hand, the specimen’s criteria selection may lead to different results. Alternatively, this controversial result may be due to heterogeneity between patients and the small number of samples assessed in the survey. In addition, environmental factors may be influence in the other geographic region due to the interaction between gene and environmental parameters. However, additional clinical and experimental analyses are obliged to verify the implements of these SNPs on PCa progression.
Conclusion
Our findings indicated that the hsa-miR-27a and hsa-miR-125a gene variations are not increased PCa predisposition in Iranian population.
References
Berndt SI, Wang Z, Yeager M, Alavanja MC, Albanes D, Amundadottir L et al (2015) Two susceptibility loci identified for prostate cancer aggressiveness. Nat Commun 6:6889
Chen M, Fang W, Wu X, Bian S, Chen G, Lu L et al (2017) Distinct effects of rs895819 on risk of different cancers: an update meta-analysis. Oncotarget 8(43):75336–75349
Chhabra R, Dubey R, Saini N (2010) Cooperative and individualistic functions of the microRNAs in the miR-23a~27a~24-2 cluster and its implication in human diseases. Mol Cancer 9:232
Corn PG (2012) The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development. Cancer Manag Res 4:183–193
Damodaran M, Paul SFD, Venkatesan V (2018) Genetic polymorphisms in miR-146a, miR-196a2 and miR-125a genes and its association in prostate cancer. Pathol Oncol Res
Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M et al (2013) Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 45(4):385–391
Feng N, Xu B, Tao J, Li P, Cheng G, Min Z et al (2012) A miR-125b binding site polymorphism in bone morphogenetic protein membrane receptor type IB gene and prostate cancer risk in China. Mol Biol Rep 39(1):369–373
Fletcher CE, Dart DA, Sita-Lumsden A, Cheng H, Rennie PS, Bevan CL (2012) Androgen-regulated processing of the oncomir miR-27a, which targets Prohibitin in prostate cancer. Hum Mol Genet 21(14):3112–3127
Ianni M, Porcellini E, Carbone I, Potenzoni M, Pieri AM, Pastizzaro CD et al (2012) Genetic factors regulating inflammation and DNA methylation associated with prostate cancer. Prostate Cancer Prostatic Dis 16:56
Inoue Y, Watanabe M, Inoue N, Kagawa T, Shibutani S, Otsu H et al (2014) Associations of single nucleotide polymorphisms in precursor-microRNA (miR)-125a and the expression of mature miR-125a with the development and prognosis of autoimmune thyroid diseases. Clin Exp Immunol 178(2):229–235
Jiao L, Zhang J, Dong Y, Duan B, Yu H, Sheng H et al (2014) Association between miR-125a rs12976445 and survival in breast cancer patients. Am j translational research 6(6):869–875
Kote-Jarai Z, Olama AA, Giles GG, Severi G, Schleutker J, Weischer M et al (2011) Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet 43(8):785–791
Kroliczewski J, Sobolewska A, Lejnowski D, Collawn JF, Bartoszewski R (2018) microRNA single polynucleotide polymorphism influences on microRNA biogenesis and mRNA target specificity. Gene 640:66–72
Kwon EM, Salinas CA, Kolb S, Fu R, Feng Z, Stanford JL et al (2011) Genetic polymorphisms in inflammation pathway genes and prostate cancer risk. Cancer Epidemiol Biomark Prev 20(5):923–933
Lehmann TP, Korski K, Ibbs M, Zawierucha P, Grodecka-Gazdecka S, Jagodzinski PP (2013) rs12976445 variant in the pri-miR-125a correlates with a lower level of hsa-miR-125a and ERBB2 overexpression in breast cancer patients. Oncol Lett 5(2):569–573
Liu Y, Guo X, Xing M, Zhao K, Luo L, Du J (2018) Prognostic value of serum levels of soluble MICA (sMICA) in patients with prostate cancer. Br J Biomed Sci 75(2):98–100
Ma JF, Zang LN, Xi YM, Yang WJ, Zou D (2016) MiR-125a Rs12976445 polymorphism is associated with the apoptosis status of nucleus pulposus cells and the risk of intervertebral disc degeneration. Cell Physiol Biochem 38(1):295–305
Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3):1215
Myatt SS, Wang J, Monteiro LJ, Christian M, Ho KK, Fusi L et al (2010) Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Can Res 70(1):367–377
Nouri R, Ghorbian S (2019) Association of single nucleotide polymorphism in hsa-miR-499 and hsa-miR-196a2 with the risk of prostate cancer. Int Urol Nephrol 51(5):811–816
Ni J, Bucci J, Chang L, Malouf D, Graham P, Li Y (2017) Targeting MicroRNAs in prostate cancer radiotherapy. Theranostics 7(13):3243–3259
Nikolic Z, Savic Pavicevic D, Vucic N, Cidilko S, Filipovic N, Cerovic S et al (2015) Assessment of association between genetic variants in microRNA genes hsa-miR-499, hsa-miR-196a2 and hsa-miR-27a and prostate cancer risk in Serbian population. Exp Mol Pathol 99(1):145–150
Odar K, Bostjancic E, Gale N, Glavac D, Zidar N (2012) Differential expression of microRNAs miR-21, miR-31, miR-203, miR-125a-5p and miR-125b and proteins PTEN and p63 in verrucous carcinoma of the head and neck. Histopathology 61:257–265
Rebbeck TR (2017) Prostate cancer genetics: variation by race, ethnicity, and geography. Semin Radiat Oncol 27(1):3–10
Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A (2004) Identification of mammalian microRNA host genes and transcription units. Genome Res 14(10a):1902–1910
Shi D, Li P, Ma L, Zhong D, Chu H, Yan F et al (2012) A genetic variant in pre-miR-27a Is associated with a reduced renal cell cancer risk in a Chinese population. PLoS ONE 7(10):e46566
Venugopal P, Lavu V, Rao SR, Venkatesan V (2017) Association of microRNA-125a and microRNA-499a polymorphisms in chronic periodontitis in a sample south Indian population: a hospital-based genetic association study. Gene 631:10–15
Wang Z, Lai J, Wang Y, Nie W, Guan X (2013) The Hsa-miR-27a rs895819 (A>G) polymorphism and cancer susceptibility. Gene 521(1):87–90
Wong MCS, Goggins WB, Wang HHX, Fung FDH, Leung C, Wong SYS et al (2016) Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. Eur Urol 70(5):862–874
Xu Q, He CY, Liu JW, Yuan Y (2013) Pre-miR-27a rs895819A/G polymorphisms in cancer: a meta-analysis. PLoS ONE 8:e65208
Zhou L, Liang X, Zhang L, Yang L, Nagao N, Wu H et al (2016) MiR-27a-3p functions as an oncogene in gastric cancer by targeting BTG2. Oncotarget 7(32):51943–51954
Acknowledgements
This article was extracted from an MS.c thesis (IR. 952003) at Ahar Branch Islamic Azad University. We would like to appreciate all the participants.
Funding
The present survey has no any fund.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interests.
Research involving human participants or animals
This article has involving human participants or animals performed by any of the authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Hakimian, M., Ghorbian, S. Negative associations between the has-miR-27a and hsa-miR-125a gene variations and prostate cancer susceptibility. Mol Biol Rep 47, 4209–4214 (2020). https://doi.org/10.1007/s11033-020-05548-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11033-020-05548-7